Evidence-Based Medical News

Mode

All Infectious Disease Oncology Neurology Cardiology Psychiatry Diabetes & Endocrinology Pediatrics Allergy & Immunology Rheumatology Gastroenterology Primary Care & Family Medicine Nutrition & Obesity Medicine Orthopedics & Sports Medicine OB/GYN & Women's Health Radiology & Imaging Genetics & Precision Medicine Pulmonology & Critical Care Anesthesiology & Pain Medicine Physical Medicine & Rehab Nephrology Hematology Urology Ophthalmology Dermatology Emergency Medicine Geriatrics & Aging ENT (Otolaryngology) Palliative Care

Research

Clinical Trials Drug Pipeline Weekly Digests

Reference

Conditions Medications

Community

Text Size

Log in / Sign up

Borderline personality disorder

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for borderline personality disorder

18 trials tracked for borderline personality disorder: 4 in phase 3 or 4 and 4 with published results. The most-cited published study has 437 citations.

18Trials tracked

4Phase 3 & 4

0Recruiting

4With published results

Phase distribution

Phase 4 2 Phase 3 2 Phase 2 6 Other / NA 8

Phase 4 Treating Suicidal Behavior and Self-Mutilation in People With Borderline Personality Disorder Completed · 437 cited
Phase 4 Comparing Treatments for Self-Injury and Suicidal Behavior in People With Borderline Personality Disorder Completed · 124 cited
Phase 3 Seroquel Extended Release (XR) for the Management of Borderline Personality Disorder (BPD) Completed · 105 cited
Phase 3 Evaluating the Safety and Tolerability of Brexpiprazole in the Treatment of Adults With Borderline Personality Disorder (BPD) Completed · 2 cited
Phase 2 A Study to Test Different Doses of BI 1358894 and Find Out Whether They Reduce Symptoms in People With Borderline Personality Disorder Completed
Phase 2 Study to Test the Efficacy and Safety of Vafidemstat in Adult Borderline Personality Disorder Population Completed

Show 12 more trials

Phase 2 A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder Completed
Phase 2 Safety and Efficacy Study of Citalopram and Lithium for the Treatment of Depressive Mood Disorder Symptoms Completed
Phase 2 Brexpiprazole in Borderline Personality Disorder Completed
Phase 2 Caplyta in Borderline Personality Disorder Completed
N/A Preschooler Emotion Regulation in the Context of Maternal Borderline Personality Disorder Completed
N/A Isolating Mechanisms in the Treatment of Borderline Personality Disorder Completed
N/A PET Imaging and Olanzapine Treatment in Borderline Personality Disorder Completed
N/A Treatment of Aggression, Anger and Emotional Dysregulation in Borderline Personality Disorder Completed
N/A Efficacy of Transference-Focused Psychotherapy for Borderline Personality Disorder Completed
N/A Mapping Aspects of Psychotherapy in Dialectical Behavior Therapy Completed
N/A Cognitive Reappraisal Training for Borderline Personality Completed
N/A Treating Self Injurious Behavior: A Novel Brain Stimulation Approach Completed

Showing the 18 most-cited and recently-updated of 18 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Borderline personality disorder: what the trials found

Quetiapine extended-release has demonstrated a statistically significant reduction in the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) scores ⁵.

Brexpiprazole was evaluated in Phase 3 and Phase 2 trials; however, results did not reach statistical significance on the ZAN-BPD scale ⁷, nor were significant changes observed in the Clinical Global Impression - Severity of Illness (CGI-S) or Patient's Global Impression of Severity (PGI-S) scales ⁷. Safety assessments for Brexpiprazole showed no significant changes in Simpson-Angus Scale (SAS), Abnormal Involuntary Movement Scale (AIMS), or Barnes Akathisia Rating Scale (BARS) scores ⁶.

Recent results — preliminary, needs further review

Vafidemstat demonstrated a statistically significant reduction in the BEST-Total Score from baseline to the average of weeks 8 to 12 ¹.
Caplyta was evaluated in a Phase 2 trial, but no outcome data were provided ².

For the clinician treating this condition

Quetiapine extended-release is supported by evidence showing significant improvement on the ZAN-BPD scale.
Brexpiprazole showed no statistically significant improvements in primary personality disorder scales (ZAN-BPD) or global severity measures (CGI-S, PGI-S).

AI synthesis of 5 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.